DeepMed Research

Galapagos

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Public

Established: 1999-01-01

Employees: 1.1K

Market Cap: $1.9B

Website: http://www.glpg.com

Introduction: Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Clinical Trials

Long-term Follow-up of Participants Treated with Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies

Phase 3

Recruiting

Conditions: Hematological Malignancies

First Posted Date: 2024-10-22

Last Posted Date: 2024-10-22

Lead Sponsor: Galapagos NV

Target Recruit Count: 546

Registration Number: NCT06652633

Locations: 🇧🇪
Antwerp University Hospital, Edegem, Belgium
🇧🇪
Centre Hospitalier Universitaire (CHU) De Liège, Liège, Belgium
🇳🇱
Amsterdam UMC, Amsterdam, Netherlands

and more 3 locations

A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Lymphomas Non-Hodgkin's B-Cell

Interventions: Genetic: GLPG5101

First Posted Date: 2024-08-20

Last Posted Date: 2025-04-23

Lead Sponsor: Galapagos NV

Target Recruit Count: 250

Registration Number: NCT06561425

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇧🇪
Antwerp University Hospital, Edegem, Belgium

and more 6 locations

Relative Bioavailability and Effect of Food Study With an Oral Mini-tablet Formulation of Filgotinib in Healthy Subjects

Phase 1

Completed

Conditions: Bioavailability

Interventions: Drug: Filgotinib

First Posted Date: 2023-09-21

Last Posted Date: 2023-11-29

Lead Sponsor: Galapagos NV

Target Recruit Count: 12

Registration Number: NCT06043739

Locations: 🇨🇦
Altasciences, Montréal, Canada

A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus

Phase 2

Active, not recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: GLPG3667
Drug: Placebo

First Posted Date: 2023-05-12

Last Posted Date: 2025-03-14

Lead Sponsor: Galapagos NV

Target Recruit Count: 186

Registration Number: NCT05856448

Locations: 🇺🇸
Desert Medical Advances, Rancho Mirage, California, United States
🇺🇸
Millennium Clinical Trials, Simi Valley, California, United States
🇺🇸
Inland Rheumatology Clinical Trials, Upland, California, United States

and more 81 locations

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

Phase 2

Active, not recruiting

Conditions: Dermatomyositis

Interventions: Drug: GLPG3667
Drug: Placebo

First Posted Date: 2023-01-25

Last Posted Date: 2025-05-18

Lead Sponsor: Galapagos NV

Target Recruit Count: 40

Registration Number: NCT05695950

Locations: 🇺🇸
HonorHealth Neurology, Scottsdale, Arizona, United States
🇺🇸
Inland Rheumatology Clinical Trials, Inc., Upland, California, United States
🇺🇸
New Access Research and Medical Center, Kendall, Florida, United States

and more 51 locations

A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission

Phase 3

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: Filgotinib
Drug: Placebo

First Posted Date: 2022-07-29

Last Posted Date: 2024-10-04

Lead Sponsor: Galapagos NV

Target Recruit Count: 22

Registration Number: NCT05479058

Locations: 🇧🇪
Universitair Ziekenhuis Leuven Campus Gasthuisberg, Leuven, Belgium
🇫🇷
CHU Amiens-Picardie, Amiens, France
🇫🇷
Hôpital Pontchaillou, Rennes, France

and more 47 locations

Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG3667 capsule
Drug: [14C]-GLPG3667 capsule
Drug: [14C]-GLPG3667 solution for infusion

First Posted Date: 2022-04-19

Last Posted Date: 2022-06-30

Lead Sponsor: Galapagos NV

Target Recruit Count: 5

Registration Number: NCT05335447

Locations: 🇬🇧
Quotient Sciences Limited, Nottingham, United Kingdom

Drug-drug Interaction Study With GLPG3667 and Itraconazole in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG3667
Drug: Itraconazole

First Posted Date: 2022-03-09

Last Posted Date: 2022-05-25

Lead Sponsor: Galapagos NV

Target Recruit Count: 14

Registration Number: NCT05272683

Locations: 🇨🇦
Altasciences, Montréal, Canada

Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG4716
Drug: Midazolam

First Posted Date: 2021-09-01

Last Posted Date: 2021-11-24

Lead Sponsor: Galapagos NV

Target Recruit Count: 19

Registration Number: NCT05030857

Locations: 🇨🇦
Altasciences, Montréal, Canada

A Study to Evaluate How Well Single and Multiple Doses of GLPG3667 Are Tolerated in Healthy, Adult Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: GLPG3667
Drug: Placebo

First Posted Date: 2021-07-26

Last Posted Date: 2022-02-14

Lead Sponsor: Galapagos NV

Target Recruit Count: 23

Registration Number: NCT04976270

Locations: 🇧🇪
Drug Research Unit Ghent, Gent, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy